Adcetris (brentuximab vedotin) / Takeda, Pfizer - LARVOL DELTA

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.)."

Journal • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain • Transplantation

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.)."

Clinical • Journal • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. (PubMed, Lancet Haematol) - P2 | "In patients with mostly CD30-expressing peripheral T-cell lymphomas other than non-anaplastic large-cell lymphoma, CHEP-BV (with or without autologous HSCT) followed by brentuximab vedotin consolidation was safe and active."

Journal • P2 data • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Transplantation • TNFRSF8

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc (clinicaltrials.gov) - P2 | N=3 | Completed | Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N=11 ➔ 3 | Recruiting ➔ Completed

Enrollment change • Trial completion • Immunology • Scleroderma • Systemic Sclerosis

Bridging the Evidence Gap in Advanced MF/SS: Stage-Stratified Treatment Patterns and Outcomes from PROCLIPI (EADV 2026) - P | "The most common first-line systemic therapies were extracorporeal photopheresis (ECP) (22.0%), methotrexate (16.8%), interferon-alpha (16.8%) and bexarotene (16.1%), together accounting for 71.7% of 410 first-line systemic treatments...The highest first-line ORRs were seen with gemcitabine (78%), romidepsin (60%) and brentuximab vedotin (60%)...Mogamulizumab achieved the highest second-line ORR (79%, n=29; median TTNsT 11.6 months), whereas the gemcitabine response rate fell from 78% at first line to 38% at second line...Sequential treatment exposure and the prevalence of combination regimens preclude attribution of overall survival to individual agents; longer follow-up and confounder-adjusted analyses will be required. Our analysis underscores the complexity of disease management and supports the need for stage-adapted treatment strategies informed by real-world prospective evidence to optimise sequencing and outcomes in this challenging patient population."

Metastases • Cutaneous T-cell Lymphoma • Dermatopathology • Mycosis Fungoides • Oncology • Sezary Syndrome • Skin Cancer

Golidocitinib Plus Brentuximab Vedotin for Brentuximab Vedotin-Refractory/Relapsed Advanced Folliculotropic Mycosis Fungoides and Sézary Syndrome: A Retrospective Cohort Study (EADV 2026) - "Responses appeared more pronounced in patients with low CD30 expression, suggesting a potential role of JAK1 inhibition in overcoming BV resistance. These findings support further prospective studies to validate Go-BV as a therapeutic strategy in advanced CTCL."

Late-breaking abstract • Metastases • Retrospective data • Cutaneous T-cell Lymphoma • Cytomegalovirus Infection • Dermatology • Dyslipidemia • Hematological Disorders • Hypertriglyceridemia • Infectious Disease • Leukopenia • Mycosis Fungoides • Oncology • Pruritus • Sezary Syndrome • Thrombocytopenia • TNFRSF8

Duality of Rarity of Chemotherapy-induced Flagellate Erythema among Cancer Patients: A Case Report with 26 Years of Evidence in Oncology. (PubMed, Curr Drug Saf) - "Healthcare professionals should be aware of and vigilant for this whip-like dermatological manifestation (FD) when choosing Bleomycin-based therapy. A patient-centric approach to cessation or rechallenge with the culprit drug, along with antihistamines and topical/ oral corticosteroids, is the mainstay for the management of FD."

Journal • Cough • Dermatitis • Dermatology • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Oncology • Respiratory Diseases

Intralesional Biologics in Dermatology: A Systematic Review (EADV 2026) - "Rituximab was the most frequently reported intralesional biologic, while other agents included adalimumab, dupilumab, brentuximab vedotin, spesolimab, secukinumab, guselkumab, bevacizumab, nivolumab, talimogene laherparepvec, and interleukin-2-based therapies. However, the currently available evidence is limited by marked heterogeneity and the predominance of low-level evidence, especially case reports. Further prospective and controlled studies are needed to better define efficacy, safety, optimal dosing strategies, and the most appropriate indications for intralesional biologic therapy in dermatology."

Review • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Extranodal Marginal Zone Lymphoma • Fibrosis • Hematological Malignancies • Immunology • Kaposi Sarcoma • Lichen Planus • Lymphoma • Marginal Zone Lymphoma • Melanoma • Mucosal Melanoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Pemphigus Vulgaris • Prurigo Nodularis • Psoriasis • Sarcoidosis • Sarcoma • Solid Tumor • IL2

Drug Rash with Eosinophilia and Systemic Symptoms Associated with Brentuximab Vedotin: A Rarely Reported Case in the Literature (EADV 2026) - "Following the diagnosis, chemotherapy with adriamycin, bleomycin, vinblastine, and dacarbazine was initiated...In consensus with the hematologydepartment, it was decided to continue brentuximab treatment, initiate systemic methylprednisolone at a dose of 32 mg/day, apply mometasone furoateointment to the erythematous maculopapular lesions on the arms and legs, and closely monitor liver and kidney function tests as well as hemogramparameters...It typically develops 2–6 weeks after exposure to the offending drug, with antiepileptics, antibiotics, NSAIDs, and allopurinol being the most frequently implicated agents...Although brentuximab vedotin is known to cause various cutaneous adverse reactions, DRESS associated with this agent has been reported only rarely. This case highlights the importance of recognizing DRESS in patients receiving brentuximab vedotin who develop fever, rash, and systemic involvement, emphasizing the need for early diagnosis and prompt treatment to..."

Clinical • Cardiovascular • Cutaneous T-cell Lymphoma • Eosinophilia • Hematological Malignancies • Immunology • Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Brentuximab vedotin-induced pustular eruption in transformed mycosis fungoides: a diagnostic challenge (EADV 2026) - "Prior mogamulizumab exposure has been associated with earlier onset of brentuximab vedotin-related rash, a pattern also seen in our patient, who developed the eruption 38 days after initiation (reported median of 43 days). Severe skin reactions to brentuximab vedotin are exceptional but must be recognized, as they can be mistaken for a flare of the tumoral disease."

Cutaneous T-cell Lymphoma • Dermatology • Eosinophilia • Mycosis Fungoides • Oncology • TNFRSF8

Intralesional Methotrexate for the Treatment of Thick Plaque Mycosis Fungoides: Revisiting an Underutilized Classic (EADV 2026) - "Other treatments include brentuximab, mogamulizumab, chemotherapy, and stem cell transplantation...During his treatment course, the patient was referred to hemato-ocology and low dose gemcitabine in six cycles was given...In the case presented, it was shown effective in thick plaques with large cell transformation. Methotrexate is an easy and available option that can be utilized in recalcitrant isolated plaques and tumors and in transformation."

Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Persistent alopecia following brentuximab vedotin–containing chemotherapy: a survivorship issue with significant psychosocial impact (ESMO 2026) - No abstract available

Oncology

Sequential lymphoid neoplasms mimicking relapse of mediastinal grey zone lymphoma in a patient with germline variants in EP300 and PTPRK. (PubMed, Virchows Arch) - "Interestingly, the shared variants were likely germline rather than clonal, suggesting they created a permissive background predisposing to two independent transforming events along the B- and T-cell lineages. Molecular studies may help to reveal the genetic basis of composite lymphomas and to resolve diagnostically discordant, complex presentations."

Journal • Hematological Malignancies • Lymphoma • Oncology • Skin Cancer • BTG2 • EP300 • JAK1 • NFKBIA • PTPRK

E4412: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=146 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ Jun 2027 | Trial primary completion date: Dec 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • CD4

Diagnostic Value of [¹⁸F]FDG PET/CT in Immunotherapy-Related Meningoencephalitis: A Paediatric Case Report (EANM 2026) - "Materials and We report the case of a 15-year-old boy diagnosed with classical Hodgkin lymphoma undergoing second-line chemotherapy with brentuximab and nivolumab, who presented to the emergency department with headache and vomiting. This case highlights the complementary role of [¹⁸F]FDG PET/CT in the evaluation of indeterminate MRI findings in neuro-oncological patients. In line with existing literature, [18F]FDG PET/CT may detect and characterize metabolic alterations associated with immune-related neurotoxicity, supporting the differential diagnosis and contributing to treatment response assessment. Its integration into the diagnostic pathway may enhance clinical decision-making in complex cases."

Case report • Clinical • FDG PET • Classical Hodgkin Lymphoma • CNS Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Pediatrics

Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma. (PubMed, Br J Haematol) - "Brentuximab vedotin (BV)-doxorubicin, vinblastine and dacarbazine (AVD) and nivolumab (N)-AVD have transformed the frontline treatment of advanced-stage Hodgkin lymphoma (HL), yet real-world comparative data remain limited. Survival outcomes were consistent in a 1:1 propensity score-matched cohort. These real-world data demonstrate comparable survival between regimens, with numerically improved PFS supporting N-AVD as a frontline standard for advanced-stage HL; however, higher rates of neutropenia and infections warrant careful monitoring and consideration of growth factor prophylaxis."

Journal • Real-world evidence • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pain • Pediatrics

Primary Cutaneous Lymphomas and Lymphoproliferative Disorders: Current Insights for Classification and Management. (PubMed, Cancers (Basel)) - "Integrating the updated diagnostic classifications with modern risk-stratified and targeted treatment paradigms is crucial for optimizing clinical management and avoiding overtreatment in indolent PCLs while improving survival in aggressive subtypes."

Journal • Review • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Dermatology • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type • T Cell Non-Hodgkin Lymphoma • CD4 • CD8

Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature. (PubMed, J Hematop) - "Primary bladder ALK + ALCL is exceedingly rare in children. Uniform CD30 positivity and ALK positivity are the key diagnostic clues."

Journal • Review • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Pediatrics • Urology • ALK • CD5 • PTPRC • TNFRSF8

Diffuse Large B-cell Lymphoma (ASH 2026) - "He will consider where approved treatments such as polatuzumab vedotin in combination with bendamustine-rituximab, loncastuximab tesirine, tafasitamab-lenalidomide, and brentuximab vedotin with lenalidomide-rituximab fit into current management algorithms. He will also discuss promising agents under investigation, including novel therapies targeting B-cell receptor signaling, apoptosis, and lineage-restricted transcription factors. This talk will also review combination strategies being explored to overcome treatment resistance."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial (ASH 2025) - "We reportefficacy outcomes for 177 patients receiving 2nd-line treatment after prior reporting of progression in theGAIA/CLL13 trial.In the GAIA/CLL13 trial, 926 physically fit patients with CLL and without TP53 aberration were randomizedbetween 1st-line treatment with chemoimmunotherapy (CIT, n=229), rituximab-venetoclax (RV, n=237),obinutuzumab-venetoclax (GV, n=229), and GV-ibrutinib (GIV, n=231)...The 13 patients with progression as Richter's transformation received R-CHOP-like therapy(n=8), ABVD-like therapy (n=2), brentuximab, rituximab-venetoclax or allogeneic stem cell transplant (n=1each).For patients who had received CIT in 1st-line treatment, 1 received CIT again, 34 received BTK inhibitor-based, 22 received venetoclax-based, and 5 received venetoclax + BTK inhibitor therapy...The majority received acalabrutinib + venetoclax (AV, n=24); 2 received AV +obinutuzumab as 2nd-line treatment.The 2-year TFS2 rate was 21.4% for CIT, 76.6% for BTK inhibitor-based,..."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Leukemia • Rare Diseases • Richter's Syndrome • CD20 • TP53

RESULTS FROM THE DOSE-FINDING PART OF LuminICE-203 PHASE 2 STUDY: ACIMTAMIG (AFM13) IN COMBINATION WITH AlloNK (AB-101) IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA (ICML 2025) - P2 | "Introduction: New therapeutic options are needed for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who progress following standard systemic therapies including chemotherapy, brentuximab vedotin (BV), and checkpoint inhibitors. The combination of acimtamig and AlloNK has shown promising efficacy with a well-managed safety profile, indicating potential therapeutic benefits and offering hope for patients with R/R cHL who have exhausted standard-of-care treatment options."

Clinical • Combination therapy • P2 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • FCGR3A • TNFRSF8

CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY (EHA 2023) - P1 | "Despite the excellent efficacy of PD-1 or PD-L1 inhibitors and brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (cHL), some patients (pts) still have disease progression. IBI322 monotherapy showed a promising anti-tumor effectivity with a manageable safety profile in anti-PD-1 or PD-L1 treatment-resistant classical Hodgkin Lymphoma patients. Clinical trial information: NCT04795128 Hodgkin's lymphoma, Resistance, Immune therapy"

P1 data • Anemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • SIRPA

INITIAL RESULTS OF THE LUMINICE-203 STUDY INVESTIGATING ACIMTAMIG WITH OFF-THE-SHELF ALLOGENEIC NATURAL KILLER CELLS (ALLONK®) IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (EBMT 2025) - P2 | "Background: Patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who progress following chemotherapy, brentuximab vedotin (BV) and PD-1 inhibitors require novel treatment options...After lymphodepletion treatment with fludarabine/cyclophosphamide (Days −5 to −3) AlloNK and acimtamig are co-administered on Days 1, 8, and 15, followed by acimtamig only on Days 22, 29 and 36 of a 58-day cycle, for up to 3 cycles... Acimtamig plus AlloNK exhibits promising efficacy and tolerability in heavily pretreated patients. Combining acimtamig with a scalable, off-the-shelf NK-cell product has the potential to address a high unmet need in patients with R/R cHL who otherwise have no SOC option. The study is ongoing"

Classical Hodgkin Lymphoma • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Oncology • FCGR3A • TNFRSF8

AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY (ICML 2023) - P2 | "Patients had received a mean of 2.7 prior treatment lines; 46.3% received prior brentuximab vedotin (BV), 17.6% received prior auto-transplant. AFM13 monotherapy demonstrated robust clinical activity in heavily pretreated patients with R/R PTCL. The safety profile of AFM13 was well managed and consistent with previously reported data from prior and ongoing clinical studies with AFM13. These data support future evaluation of AFM13 in combination with other immunotherapies, including allogeneic NK cells, to further potentiate anti-tumor immune responses to CD30+ lymphomas."

Clinical • IO biomarker • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • FCGR3A • TNFRSF8

Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma (ASH 2022) - P1/2 | "Patients aged 15–75 years with R/R CD30+ lymphomas refractory to brentuximab vedotin are enrolled...Each treatment cycle consisted of fludarabine/cyclophosphamide (days −5 to −3), followed by infusion of the AFM13-NK cells, cultured for 14 days as described above (day 0), and three weekly IV infusions of AFM13 (200 mg, days 7, 14 and 21)... This is the first clinical trial to date using an ICE® construct precomplexed with cytokine-induced memory-like CB-NK cells to treat patients with CD30+ R/R HL and NHL. Our preliminary results indicate that this ICE® precomplexed CB-NK cell therapy has an excellent tolerability profile and is highly active in patients with heavily pretreated R/R CD30+ lymphomas and warrants further investigation."

Clinical • IO biomarker • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • FCGR3A • IL12A • IL15 • IL18 • IL21 • TNFRSF8